La Roche Posay Laboratoire Dermatologique Effaclar Clarifying

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleaned prior to the application of this product. The affected area should be covered with a thin layer of the product one to three times daily, depending on the patient's needs and the physician's recommendations.

It is advisable to initiate treatment with one application per day to minimize the risk of excessive drying of the skin. Based on the patient's response, the frequency of application may be gradually increased to two or three times daily.

In cases where bothersome dryness or peeling occurs, it is recommended to reduce the frequency of application to once daily or every other day to alleviate these symptoms.

Contraindications

There are no specific contraindications identified for this product. However, it is advised that if the product is swallowed, medical assistance should be sought immediately or contact a Poison Control Center. Additionally, in the event of skin irritation, it is recommended to use only one topical acne medication at a time to avoid exacerbating the condition.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to adhere strictly to this guideline to prevent unintended systemic exposure.

In the event of accidental ingestion, immediate medical assistance should be sought. Patients should be instructed to contact a Poison Control Center or seek emergency medical help without delay.

Healthcare providers should be aware that the concurrent use of this product with other topical acne medications may increase the risk of skin irritation and dryness. It is recommended that only one topical acne medication be used at a time to minimize the potential for adverse skin reactions. Should irritation occur, patients should discontinue use and consult their healthcare provider for further guidance.

No specific laboratory tests are recommended for monitoring the use of this product. However, healthcare professionals should remain vigilant for any signs of adverse reactions in patients and provide appropriate management as necessary.

Side Effects

Patients should be advised that the product is for external use only. This warning is critical to ensure safe and appropriate use, as improper application may lead to adverse effects not specified in the available data. No additional adverse reactions have been reported in clinical trials or postmarketing experiences.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of La Roche Posay Laboratoire Dermatologique Effaclar Clarifying (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily. Dosage may be gradually increased to two or three times daily as needed or directed by a healthcare professional. Care should be taken to observe for excessive drying of the skin; if bothersome dryness or peeling occurs, the frequency of application should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of this product during pregnancy has not been established. The use of salicylic acid during pregnancy is generally not recommended due to potential risks to the fetus. There may be a risk of teratogenic effects associated with the use of salicylic acid in pregnant women. Therefore, pregnant women should consult a healthcare provider before using this product to discuss potential risks and benefits.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

If the substance involved is known, specific antidotes or treatments may be indicated, and healthcare professionals should refer to established guidelines for the management of overdose related to that substance.

In all cases, contacting a poison control center or a medical toxicologist for guidance is recommended to ensure appropriate management and intervention.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event of swallowing the medication, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Patients should also be informed about the potential for skin irritation and dryness, particularly if they are using another topical acne medication concurrently. It is important to counsel patients to use only one topical acne medication at a time to minimize the risk of irritation.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with a recommended application of a thin layer to the entire affected area one to three times daily. Patients should begin with one application daily and may gradually increase to two or three times daily as needed or directed by a clinician. If bothersome dryness or peeling occurs, it is advised to reduce the frequency to once a day or every other day.

Clinicians should counsel patients regarding sun exposure, as the product contains an alpha hydroxy acid (AHA) that may heighten skin sensitivity to the sun, increasing the risk of sunburn. Patients are advised to use sunscreen, wear protective clothing, and limit sun exposure during treatment and for one week following discontinuation.

Drug Information (PDF)

This file contains official product information for La Roche Posay Laboratoire Dermatologique Effaclar Clarifying, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)